cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.10255961.v1
title: Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin

description: <b>Background</b>: Vildagliptin is a dipeptidyl peptidase-4 inhibitor that reduces glycemia in patients with type 2 diabetes mellitus (T2DM). When approved in 2013, data on vildagliptin combined with &gt;750 mg/day metformin in Japanese patients were limited. There is a need to confirm the safety and efficacy of vildagliptin in combination with oral antidiabetic drugs (OADs). <b>Research design and methods</b>: This 52-week post-marketing surveillance (PMS) observational study in Japanese T2DM patients evaluated the safety and efficacy of vildagliptin in combination with OADs including high-dose metformin or insulin but excluding combination with sulfonylureas alone. <b>Results</b>: During this survey of 3006 Japanese T2DM patients, 13.61% of patients experienced adverse events (AEs) and 2.20% reported a serious AE (SAE). The frequency of AEs/SAEs was similar when in combination with biguanides (12.93%/1.46%), metformin ≥1000 mg/day (12.92%/1.22%), metformin &lt;1000 mg/day (12.62%/1.54%), thiazolidine derivatives (16.71%/2.86%), α-glucosidase inhibitors (13.18%/1.90%), rapid-acting insulin secretagogues (glinides) (20.41%/5.71%), or insulin (15.87%/2.47%). The mean ± SD changes from baseline at endpoint in glycated hemoglobin and fasting blood glucose were −0.76 ± 1.27% and −23.3 ± 57.3 mg/dL, respectively, and these changes were consistent, regardless of concomitant OAD. <b>Conclusions</b>: Long-term vildagliptin combination therapy is safe and effective in Japanese T2DM patients in real-world settings.
DOI: 10.5281/zenodo.4742171
title: EMUE-D2-2-CorrectionFactors

description: A common form of presentation for calibration results involves expressing the result as an additive or multiplicative correction. This is the case for vacuum gauges and is illustrated with data using the models described in [1]. The examples and conclusions do, however, have much wider applicability. This example demonstrates the effect of model assumptions concerning errors in the reference value. In addition, it demonstrates how conformance probability can be affected by these assumptions. The example concludes by demonstrating how correlation can be handled for calibration corrections. Files contained in the dataset are: “EMUE A1.2.2 Additive or multiplicative corrections.zip”: Zip file containing .tex, .bib and image files “A122.bib”: Bibliography file “EMUE A1.2.2 Additive and multiplicative corrections.tex”: LaTeX file “EMUE_A1_2_2_Additive_or_multiplicative_corrections.pdf”: Report - Measurement models involving additive or multiplicative corrections “EMUE 1.2.2 correlated example.pdf”: PDF of Mathcad document used to perform calculations in section 7
description: Calculations in the majority of this example are performed by substitution of values into equations provided in the text or through use of standard tabulated values. No software was written for the purpose of performing these calculations which can be made, for example, using standard Excel function cell functions. Section 7 is presented in terms of matrices. The calculation has been performed using Mathcad 7. In view of the lack of backward compatibility and the existence of multiple versions of Mathcad, the calculation is provided as a pdf 'script' which should be straightforward to reproduce.
DOI: 10.5281/zenodo.4742170
title: EMUE-D2-2-CorrectionFactors

description: A common form of presentation for calibration results involves expressing the result as an additive or multiplicative correction. This is the case for vacuum gauges and is illustrated with data using the models described in [1]. The examples and conclusions do, however, have much wider applicability. This example demonstrates the effect of model assumptions concerning errors in the reference value. In addition, it demonstrates how conformance probability can be affected by these assumptions. The example concludes by demonstrating how correlation can be handled for calibration corrections. Files contained in the dataset are: “EMUE A1.2.2 Additive or multiplicative corrections.zip”: Zip file containing .tex, .bib and image files “A122.bib”: Bibliography file “EMUE A1.2.2 Additive and multiplicative corrections.tex”: LaTeX file “EMUE_A1_2_2_Additive_or_multiplicative_corrections.pdf”: Report - Measurement models involving additive or multiplicative corrections “EMUE 1.2.2 correlated example.pdf”: PDF of Mathcad document used to perform calculations in section 7
description: Calculations in the majority of this example are performed by substitution of values into equations provided in the text or through use of standard tabulated values. No software was written for the purpose of performing these calculations which can be made, for example, using standard Excel function cell functions. Section 7 is presented in terms of matrices. The calculation has been performed using Mathcad 7. In view of the lack of backward compatibility and the existence of multiple versions of Mathcad, the calculation is provided as a pdf 'script' which should be straightforward to reproduce.
DOI: 10.5258/soton/d1645
title: Dataset for: High Gain Bi-Doped Fiber Amplifier Operating in the E-band with a 3-dB Bandwidth of 40nm

description: This dataset supports the publication: Yu Wang, Naresh K Thipparapu, David J Richardson, Jayanta Sahu. (2021) High Gain Bi-Doped Fiber Amplifier Operating in the E-band with a 3-dB Bandwidth of 40nm. In: OFC 2021
DOI: 10.21227/vvfc-nk59
title: VOT raw results

description: VOT raw results
DOI: 10.5517/cc77vt3
title: CCDC 216095: Experimental Crystal Structure Determination

description: Related Article: L.R.Wen, M.Li, W.Wang, G.L.Zhao, X.M.Li, S.S.Zhang, H.Xu, P.K.Ouyang|2005|Indian J.Chem.,Sect.B:Org.Chem.Incl.Med.Chem.|44|1098|
DOI: 10.5517/ccdc.csd.cc26rynl
title: CCDC 2048810: Experimental Crystal Structure Determination

description: Related Article: Satish Kumar Patel|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc10blpm
title: CCDC 933710: Experimental Crystal Structure Determination

description: Related Article: James A. Starnes, Eric W. Reinheimer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc2737sd
title: CCDC 2058703: Experimental Crystal Structure Determination

description: Related Article: H.BOURAOUI|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc2737vg
title: CCDC 2058705: Experimental Crystal Structure Determination

description: Related Article: Mark Bartolo, Stephen Tsui, Eric W. Reinheimer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273c4w
title: CCDC 2058807: Experimental Crystal Structure Determination

description: Related Article: Leandri Liebenberg|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273c80
title: CCDC 2058811: Experimental Crystal Structure Determination

description: Related Article: Leandri Liebenberg|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273gqk
title: CCDC 2058918: Experimental Crystal Structure Determination

description: Related Article: James A. Starnes, Ryan H. Groeneman, Eric W. Reinheimer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273gzt
title: CCDC 2058926: Experimental Crystal Structure Determination

description: Related Article: A. Perez-Benitez, S. Bernes, R.E.Arroyo Carmona|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273h0w
title: CCDC 2058927: Experimental Crystal Structure Determination

description: Related Article: K.M. German Tepetla, J.J. Vazquez Bravo, A. Perez-Benitez, S. Bernes|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273j52
title: CCDC 2058963: Experimental Crystal Structure Determination

description: Related Article: James A. Starnes, Ryan H. Groeneman, Eric W. Reinheimer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273j63
title: CCDC 2058964: Experimental Crystal Structure Determination

description: Related Article: James A. Starnes, Ryan H. Groeneman, Eric W. Reinheimer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273jb7
title: CCDC 2058968: Experimental Crystal Structure Determination

description: Related Article: James A. Starnes, Ryan H. Groeneman, Eric W. Reinheimer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273jhd
title: CCDC 2058973: Experimental Crystal Structure Determination

description: Related Article: Dylan Kimball, Ryan H. Groeneman, Eric W. Reinheimer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273k0y
title: CCDC 2058989: Experimental Crystal Structure Determination

description: Related Article: Eric W. Reinheimer, Kim R.Dunbar|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc2738rd
title: CCDC 2058733: Experimental Crystal Structure Determination

description: Related Article: Nagham Alatrash, Frederick M. Macdonnell|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273s5b
title: CCDC 2059211: Experimental Crystal Structure Determination

description: Related Article: A. Perez-Benitez, I. Angel Nieto, S. Bernes |2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273s7d
title: CCDC 2059213: Experimental Crystal Structure Determination

description: Related Article: A. Perez-Benitez, I. Angel Nieto, S. Bernes |2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273s9g
title: CCDC 2059215: Experimental Crystal Structure Determination

description: Related Article: A. Perez-Benitez, I. Angel Nieto, S. Bernes |2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc273wv3
title: CCDC 2059325: Experimental Crystal Structure Determination

description: Related Article: xiaojing xu|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc27mcs1
title: CCDC 2074203: Experimental Crystal Structure Determination

description: Related Article: Maxim I. Rogovoy, Alexey S. Berezin, Denis G. Samsonenko, Alexander V. Artem’ev|2021|Inorg.Chem.|60|6680|doi:10.1021/acs.inorgchem.1c00480
DOI: 10.6084/m9.figshare.12993160
title: Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?

description: A growing number of antidiabetic agents have demonstrated cardiovascular and renal benefits in cardiovascular outcome trials (CVOTs), despite such trials being principally required to rule out excess cardiovascular risk. This article addresses the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS-CV) trial, its background, design, results, and implications. In patients at least 40 years of age with atherosclerotic cardiovascular disease (ASCVD), the VERTIS-CV trial demonstrated ertugliflozin was non-inferior to placebo for major adverse cardiovascular events, though not superior. Ertugliflozin significantly reduced hospitalization for heart failure compared to placebo. The composite renal outcome was not significantly different between groups. Ertugliflozin was generally well tolerated with a safety profile commensurate with other sodium-glucose co-transporter-2 inhibitors (SGLT-2) inhibitors. In patients with type 2 diabetes and ASCVD, ertugliflozin appears safe with a noted non-significant trend toward improved renal outcomes. Approximately 23.7% of patients in the VERTIS-CV trial had heart failure, the highest among SGLT-2 inhibitor CVOTs. The VERTIS-CV trial reaffirms the reduction in heart failure hospitalizations as a likely class effect of SGLT-2 inhibitors. While the trial supports the use of ertugliflozin beyond glycemic control, agents with confirmed superiority for improved cardiovascular outcomes and mortality may be preferred.
DOI: 10.6084/m9.figshare.12993160.v1
title: Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?

description: A growing number of antidiabetic agents have demonstrated cardiovascular and renal benefits in cardiovascular outcome trials (CVOTs), despite such trials being principally required to rule out excess cardiovascular risk. This article addresses the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS-CV) trial, its background, design, results, and implications. In patients at least 40 years of age with atherosclerotic cardiovascular disease (ASCVD), the VERTIS-CV trial demonstrated ertugliflozin was non-inferior to placebo for major adverse cardiovascular events, though not superior. Ertugliflozin significantly reduced hospitalization for heart failure compared to placebo. The composite renal outcome was not significantly different between groups. Ertugliflozin was generally well tolerated with a safety profile commensurate with other sodium-glucose co-transporter-2 inhibitors (SGLT-2) inhibitors. In patients with type 2 diabetes and ASCVD, ertugliflozin appears safe with a noted non-significant trend toward improved renal outcomes. Approximately 23.7% of patients in the VERTIS-CV trial had heart failure, the highest among SGLT-2 inhibitor CVOTs. The VERTIS-CV trial reaffirms the reduction in heart failure hospitalizations as a likely class effect of SGLT-2 inhibitors. While the trial supports the use of ertugliflozin beyond glycemic control, agents with confirmed superiority for improved cardiovascular outcomes and mortality may be preferred.
DOI: 10.34808/9825-3x95
title: Number of individual clients who have signed an agreement enabling the use of internet banking (2017)

description: The  data show that at the end of 2017, 32.5 million people in Poland had the opportunity to use internet banking, i.e. signed an agreement enabling the use of internet banking. It is worth noting, however, that the so-called passive users - people who have access, but do not have to log into their account via an internet connection.
The largest number of people who had access to this type of solution was served by PKO BP Bank, however, what is important, taking into account the dedicated brand, ie Inteligo (the separation of this sales channel was intended to promote electronic and mobile banking). Only two banks listed in the ranking lost users with access to this channel (ie T-Mobile banking services and mBank), by a total of approximately 0.5 million people.
DOI: 10.34808/6hmd-f563
title: Number of individual clients in Polish banks (10 largest entities) in 2017

description: According to the data of the National Bank of Poland, in 2017 Polish banks served 49 million customers (of which 45.5 million were retail customers). The largest number of individual clients was served by PKO Bank Polski - nearly 9.5 million, the second was Bank Pekao - 5.4 million, and the third place in the list of ING Bank Śląski - 4.6 million. A significant part of the banks recorded a quarterly increase from several thousand to several dozen thousand new customers. Banks maintained a total of 31.7 million accounts (the so-called ROR - checking and savings account). Most of them are PKO BP, which currently maintains 7.1 million accounts. Bank Pekao is second (3.87 million personal accounts), and third is mBank (3.30 million)
DOI: 10.34808/mb56-0f49
title: The number of individual clients who log in to the bank using internet banking at least once a month (2017)

description: Taking into account active users, i.e. those who have used Internet access at least once, the situation is a bit different. Out of 32.5 million people who have access to electronic banking, 14.7 million people worked at least once a month (data as at the end of 2017). It is worth noting, however, that in this group there was also an increase in the number of users, i.e. 0.7 million people. As in the case of the number of previous data, the leader in the number of active internet banking users is PKO BP (along with the Inteligo brand).
DOI: 10.34808/yg7z-ty35
title: The number of financial transactions made from the level of the mobile application in 2017

description: Taking into account the number of transactions made, the increase is almost 100% when using the mobile application. In 2017, 44 million people were recorded financial transactions made via the application, i.e. opening a deposit or ordering a transfer. It should therefore be noted that there is a growing interest in ordering certain transactions via mobile devices.
DOI: 10.34808/7h6k-6772
title: Number of mobile banking users who log into the bank at least once a month from a mobile device (telephone or smartphone) - 2017

description: Electronic banking should be understood broadly. Therefore, taking into account also other channels, the number of users using mobile electronic devices (smartphone, tablet) should be mentioned. Also in this case, there was an increase in the number of people using this channel of access to their bank account. At the end of 2017, nearly 9 million people logged in to the bank using a mobile device at least once a month - an increase of over 2 million people compared to the previous year.
DOI: 10.34808/pg0b-9109
title: Number of customers using only mobile devices (so-called "mobile only") - 2017

description: The number of users who only use mobile devices is also growing (excluding access via desktop computers and people who manage to order current transactions in traditional bank branches). At the end of the fourth quarter 2017, there were 2.2 million such people - an increase by 434 thousand. compared to previous year.
DOI: 10.5281/zenodo.4742237
title: Patient involvement and malpractice complaints anonymized minimal data and do file

description: Anonymized minimal data and do file for analyses in manuscript about patient involvement and malpractice complaints
DOI: 10.5281/zenodo.4742238
title: Mineraldata: Including elastic data of Fe-bearing opx

description: Elastic data of Fe-bearing opx is included
DOI: 10.5281/zenodo.4742236
title: Patient involvement and malpractice complaints anonymized minimal data and do file

description: Anonymized minimal data and do file for analyses in manuscript about patient involvement and malpractice complaints
DOI: 10.5281/zenodo.4600381
title: Mineraldata: Including elastic data of Fe-bearing opx

description: Elastic data of Fe-bearing opx is included
DOI: 10.34808/j3p9-6r10
title: Number of active users of the mobile banking application (only a mobile phone) - 2017

description: Customers using mobile devices can use their bank account via the bank's website or a separate application. Such a solution allows for easier logging in (usually no customer number is required, but only a password) and a number of additional functions (from a more extensive interface to a larger number of possible operations - making a transfer, opening a deposit, taking a relatively small loan).
This access channel also saw an increase in the number of users. At the end of 2017, the number of people actively using applications installed on mobile phones amounted to 5.5 million people and increased by nearly 2.5 million compared to the previous year.
DOI: 10.6084/m9.figshare.14555110.v1
title: GSER_Supplementary_file_1 from A Genome Size Estimator using R: a pipeline for quality assessment of sequenced genome libraries through genome size estimation

description: Description of the downloaded and processed SRA accessions of the DNA-Seq read datasets from Human, Fruit fly, Rice and African clawed frog Xenopus laevis (Real reads datasets).
DOI: 10.6084/m9.figshare.14555110
title: GSER_Supplementary_file_1 from A Genome Size Estimator using R: a pipeline for quality assessment of sequenced genome libraries through genome size estimation

description: Description of the downloaded and processed SRA accessions of the DNA-Seq read datasets from Human, Fruit fly, Rice and African clawed frog Xenopus laevis (Real reads datasets).
DOI: 10.6084/m9.figshare.14555119.v1
title: GSER_Supplementary_file_2 from A Genome Size Estimator using R: a pipeline for quality assessment of sequenced genome libraries through genome size estimation

description: Description of the downloaded SRA accessions of the DNA-Seq read datasets from African clawed frog Xenopus laevis used to generate simulated (Ideal) read datasets; command lines used in ART simulator of reads.
DOI: 10.6084/m9.figshare.14555119
title: GSER_Supplementary_file_2 from A Genome Size Estimator using R: a pipeline for quality assessment of sequenced genome libraries through genome size estimation

description: Description of the downloaded SRA accessions of the DNA-Seq read datasets from African clawed frog Xenopus laevis used to generate simulated (Ideal) read datasets; command lines used in ART simulator of reads.
DOI: 10.6084/m9.figshare.14555124
title: FGGA-lnc Code from FGGA-lnc: automatic gene ontology annotation of lncRNA sequences based on secondary structures

description: This file contains the R code to characterize the lncRNA sequences
DOI: 10.34808/m0dv-2b07
title: Number of active HCE cards installed in mobile phones (2017)

description: HCE technology (Host Card Emulation), which enables contactless payments by phone in a similar way as in the case of a payment card. At the time of making the transaction, the phone is close to the terminal, practically the same as the payment card. This solution, like the others described previously, should be included in the elements of electronic banking. In Poland, this mechanism is gaining popularity, at the end of 2017, 0.85 million Poles actively used HCE cards. Compared to the same period in 2016, a threefold increase in users was recorded. The largest number of customers using this solution was recorded in Bank Pekao S.A.
DOI: 10.6084/m9.figshare.14555121
title: Mouse dataset from FGGA-lnc: automatic gene ontology annotation of lncRNA sequences based on secondary structures

description: This dataset contains the sequences characterized by FGGA-lnc and the associated GO-terms
DOI: 10.6084/m9.figshare.14555124.v1
title: FGGA-lnc Code from FGGA-lnc: automatic gene ontology annotation of lncRNA sequences based on secondary structures

description: This file contains the R code to characterize the lncRNA sequences
DOI: 10.6084/m9.figshare.14555127
title: Zebrafish dataset from FGGA-lnc: automatic gene ontology annotation of lncRNA sequences based on secondary structures

description: This dataset contains the sequences characterized by FGGA-lnc and the associated GO-terms
DOI: 10.6084/m9.figshare.14555121.v1
title: Mouse dataset from FGGA-lnc: automatic gene ontology annotation of lncRNA sequences based on secondary structures

description: This dataset contains the sequences characterized by FGGA-lnc and the associated GO-terms
DOI: 10.6084/m9.figshare.14555130
title: Wild pig dataset from FGGA-lnc: automatic gene ontology annotation of lncRNA sequences based on secondary structures

description: This dataset contains the sequences characterized by FGGA-lnc and the associated GO-terms
DOI: 10.6084/m9.figshare.14555133
title: Human dataset from FGGA-lnc: automatic gene ontology annotation of lncRNA sequences based on secondary structures

description: This dataset contains the sequences characterized by FGGA-lnc and the associated GO-terms
DOI: 10.6084/m9.figshare.14555133.v1
title: Human dataset from FGGA-lnc: automatic gene ontology annotation of lncRNA sequences based on secondary structures

description: This dataset contains the sequences characterized by FGGA-lnc and the associated GO-terms
DOI: 10.6084/m9.figshare.14555130.v1
title: Wild pig dataset from FGGA-lnc: automatic gene ontology annotation of lncRNA sequences based on secondary structures

description: This dataset contains the sequences characterized by FGGA-lnc and the associated GO-terms
DOI: 10.6084/m9.figshare.14555127.v1
title: Zebrafish dataset from FGGA-lnc: automatic gene ontology annotation of lncRNA sequences based on secondary structures

description: This dataset contains the sequences characterized by FGGA-lnc and the associated GO-terms